Drugs / Vonorasan
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06783257 | Feb 2025 → Feb 2027 expected | active peptic ulcer disease | Shandong New Time Pharmaceutical Co., LTD | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06481787 | Jun 2024 → Apr 2026 | depressive disorder, gastroesophageal reflux disease | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vonorasan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06783257 ↗ |
| Known as | Vonorasan fumarate | “Vonorasan fumarate injection1” NCT06783257 ↗1“Drug: Vonorasan Fumarate” NCT06481787 ↗ |
| Route | Intravenous | “ivd，30min，q24h，administered for 3 days” NCT06783257 ↗ |